# Cardiac amyloidosis

Condition · id `cardio:cardiac-amyloidosis` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

Cardiac amyloidosis happens when an abnormal protein called amyloid builds up in the heart muscle and forms deposits. The deposits can leave the heart stiff and unable to work the way it should, and people may have an abnormal heartbeat or an enlarged heart. It is one cause of cardiomyopathy. Amyloid can build up in other organs too, such as the kidney. In the United States the label of the medicine tafamidis gives cardiomyopathy caused by one type of amyloid in adults as its indication.

## Technical summary

MeSH has no descriptor for cardiac amyloidosis. The wider descriptor Amyloidosis (D000686) is recorded here as a broad match; its scope note describes diseases linked by abnormal protein folding and deposition of amyloid. The MedlinePlus Genetics page describes a cardiac form of transthyretin amyloidosis, and the US tafamidis label names the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM). Other types of amyloidosis can also involve the heart; this page does not separate the types.

## Claims, with the population each applies to

## Context: People with amyloidosis that affects the heart, as described in MeSH and MedlinePlus reference pages

Recipient: Recipient not specified; Population: People with amyloidosis, with emphasis on involvement of the heart. The pages are written for the public or as a vocabulary and give no study population, age range or risk group. The MedlinePlus Genetics page describes the transthyretin type.; Care setting: General health information for the public; no care setting is stated; Geography: United States (pages of US government agencies); the MeSH vocabulary is international; Life stage: Not stated in the pages for the heart form; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (descriptive statement)

### The MeSH scope note for amyloidosis describes a group of diseases linked by abnormal protein folding and deposition of amyloid, with the deposits displacing normal tissue and disrupting its function. MedlinePlus says abnormal proteins called amyloids build up and form deposits, that the deposits can collect in organs such as the kidney and heart, and that this can leave an organ stiff and unable to work as it should. MedlinePlus Genetics says the cardiac form of transthyretin amyloidosis affects the heart and that people with cardiac amyloidosis may have an abnormal heartbeat and an enlarged heart.

- Category: Description
- Evidence stage: Evidence stage unknown
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: People with amyloidosis, with emphasis on involvement of the heart. The pages are written for the public or as a vocabulary and give no study population, age range or risk group. The MedlinePlus Genetics page describes the transthyretin type.; Care setting: General health information for the public; no care setting is stated; Geography: United States (pages of US government agencies); the MeSH vocabulary is international; Life stage: Not stated in the pages for the heart form; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (descriptive statement)
- Limitations: Vocabulary and patient-education pages from US government sources. MeSH has no descriptor for cardiac amyloidosis, so the scope note describes amyloidosis as a whole. The MedlinePlus Genetics page describes the transthyretin type only, and its list of cardiac findings is quoted only in part because the page's wording of the last finding looks like a source error. The pages give no study, no size of risk and no population beyond the general public.
- Last checked: 2026-10-30
- Sources:
  1. Supports: MeSH scope note for descriptor D000686 (Amyloidosis) (Dataset, edition MeSH linked-data record of the preferred concept M0001053 of descriptor D000686, fetched 2026-10-30. The scope note is on this concept record, not on the descriptor record.) <https://id.nlm.nih.gov/mesh/M0001053>
     Locator: scopeNote.@value. Retrieved 2026-10-30T19:43:18Z. Source state: Current. Version fingerprint: 54d0563e45b3bf8fa1c1bee0c833fb7035d74e96a0978f111ad84c17bac6d595.
     How it applies: MeSH scope note of the descriptor Amyloidosis, which is wider than the heart form.
  2. Supports: Amyloidosis (MedlinePlus health topic) (Webpage, edition Page fetched 2026-10-30. The page says it was last updated July 5, 2026.) <https://medlineplus.gov/amyloidosis.html>
     Locator: Summary, para 1, sentence 1. Retrieved 2026-10-30T19:43:33Z. Source state: Current. Version fingerprint: 180c57d16d5511de7fadf3cc7fe19969b5d0139c61948bd94bd9bdbea5fd3604.
     How it applies: What amyloidosis is.
  3. Supports: Amyloidosis (MedlinePlus health topic) (Webpage, edition Page fetched 2026-10-30. The page says it was last updated July 5, 2026.) <https://medlineplus.gov/amyloidosis.html>
     Locator: Summary, para 1, sentence 2. Retrieved 2026-10-30T19:43:33Z. Source state: Current. Version fingerprint: 180c57d16d5511de7fadf3cc7fe19969b5d0139c61948bd94bd9bdbea5fd3604.
     How it applies: Organs where the deposits collect.
  4. Supports: Amyloidosis (MedlinePlus health topic) (Webpage, edition Page fetched 2026-10-30. The page says it was last updated July 5, 2026.) <https://medlineplus.gov/amyloidosis.html>
     Locator: Summary, para 1, sentence 3. Retrieved 2026-10-30T19:43:33Z. Source state: Current. Version fingerprint: 180c57d16d5511de7fadf3cc7fe19969b5d0139c61948bd94bd9bdbea5fd3604.
     How it applies: Effect on the organs.
  5. Supports: Transthyretin amyloidosis (MedlinePlus Genetics) (Webpage, edition Page fetched 2026-10-30. The page says it was last updated November 8, 2023. Its paragraph on the cardiac form lists orthostatic hypertension, while its paragraph on the neuropathic form lists a sharp drop in blood pressure on standing (orthostatic hypotension), so the cardiac-form wording looks like a source error and is not used here.) <https://medlineplus.gov/genetics/condition/transthyretin-amyloidosis/>
     Locator: Description, para 4, sentence 1. Retrieved 2026-10-30T19:43:43Z. Source state: Current. Version fingerprint: 2defdb0688632ca71f852b099c8cf88007a300011d1f7ac09aee892ddf87379c.
     How it applies: The cardiac form of transthyretin amyloidosis.
  6. Supports: Transthyretin amyloidosis (MedlinePlus Genetics) (Webpage, edition Page fetched 2026-10-30. The page says it was last updated November 8, 2023. Its paragraph on the cardiac form lists orthostatic hypertension, while its paragraph on the neuropathic form lists a sharp drop in blood pressure on standing (orthostatic hypotension), so the cardiac-form wording looks like a source error and is not used here.) <https://medlineplus.gov/genetics/condition/transthyretin-amyloidosis/>
     Locator: Description, para 4, sentence 2 (first part). Retrieved 2026-10-30T19:43:43Z. Source state: Current. Version fingerprint: 2defdb0688632ca71f852b099c8cf88007a300011d1f7ac09aee892ddf87379c.
     How it applies: First two findings of the list.

## Connected pages

- Cardiac amyloidosis is a cause of cardiomyopathy: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Related condition: heart failure: Heart failure (`cardio:heart-failure`)
- Files under this front: Medicines (`cardio:front-medicines`)
- Related to: Left ventricular hypertrophy (`cardio:left-ventricular-hypertrophy`)
- Related to: Restrictive cardiomyopathy (`cardio:restrictive-cardiomyopathy`)
- Evaluated for this: Acoramidis (`cardio:acoramidis`) [a claim, not a settled fact; see claim `cardio:claim-fda-attruby-label-indications` and its context]
- Evaluated for this: Tafamidis (`cardio:tafamidis`) [a claim, not a settled fact; see claim `cardio:claim-tafamidis-label-indication` and its context]
- Related to: Transthyretin stabilizers and transthyretin-directed RNA interaction medicines (`cardio:transthyretin-directed-medicines`)
- Evaluated for this: Vutrisiran (`cardio:vutrisiran`) [a claim, not a settled fact; see claim `cardio:claim-fda-amvuttra-label-indications` and its context]

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 19 registry trials

## Provenance

Content hash: 1ec06350245a489adcab76a2036284dfa48f8db9bf2086d8307278dc2906521f
Last substantive edit: 2026-10-30
Evidence last checked: 2026-10-30
